{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:20:20Z","timestamp":1790061620898,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Carl Gustav Carus Dresden an der Technischen Universit\u00e4t Dresden"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Measurement of health-related quality of life (HRQoL) in patients with melanoma under immune checkpoint inhibitor therapy (ICI) under routine conditions and in survivorship is insufficient due to the absence of data and therapy-specific instruments in clinical trials. This pilot study aimed to collect and compare data on symptom burden and HRQoL in patients during and after ICI therapy. The benefit of a treatment-\/disease-specific item list compared to a general-oncologic HRQoL instrument was examined. The results are intended to be used for planning a longitudinal study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional, monocentric, questionnaire-based study included patients with melanoma stages II-IV treated at the University Hospital Dresden, Germany. HRQoL was measured in a treatment group (ongoing ICI therapy) and a survivor group (minimum one year therapy- and relapse-free after ICI). The treatment group was interviewed with the cancer-generic EORTC QLQ-C30 and the survivor group with the EORTC SURV100, both consisting of different scales (range 0-100). Hereby, an elevated HRQoL score indicates a better HRQoL. Additionally, a treatment-\/disease-specific PRO-CTCAE item list was conducted in both groups. We performed descriptive and exploratory analysis aiming to identify and compare symptom burden in both groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>General health measured with EORTC C30\/SURV100 in the treatment group (73 patients) was marginally lower than in the survivor group (26 patients) with a mean score of 61.0 (SD\u2009\u00b1\u200921) vs. 67.0 (SD\u2009\u00b1\u200921), which implies descriptively lower HRQoL scores in the treatment group than in clinical trials and population norm data. With almost similar demographic-clinical characteristics, the treatment group frequently reported pruritus and xerostomia, while survivors frequently reported aching joints, memory loss and a considerable emotional burden. The high prevalence of xerosis cutis, fatigue and sexual dysfunction was observed across both groups. In both groups, the specific PRO-CTCAE identified further relevant symptoms than the general instruments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Needs of patients during and after ICI therapy appear to differ with an assumed remaining symptom burden in survivors of melanoma. For measuring HRQoL a therapy-\/disease-specific instrument should be considered. Rising numbers of patients undergoing ICI therapy and survivors underscore the need for comprehensive data on HRQoL and specific aspects of treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-025-15069-w","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:16:51Z","timestamp":1760617011000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Health-related quality of life and symptom burden in patients with melanoma during and after immune checkpoint inhibitor therapy \u2013 a pilot study"],"prefix":"10.1186","volume":"25","author":[{"given":"Lea","family":"P\u00f6schmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedegund","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Eichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank Friedrich","family":"Gellrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Schoffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"issue":"4","key":"15069_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/medsci9040063","volume":"9","author":"K Saginala","year":"2021","unstructured":"Saginala K, Barsouk A, Aluru JS, Rawla P, Barsouk A. Epidemiol Melanoma Med Sci. 2021;9(4):63. https:\/\/doi.org\/10.3390\/medsci9040063.","journal-title":"Epidemiol Melanoma Med Sci"},{"issue":"7","key":"15069_CR2","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.3390\/ijms17071151","volume":"17","author":"Y Li","year":"2016","unstructured":"Li Y, Li F, Jiang F, Lv X, Zhang R, Lu A, et al. A Mini-Review for cancer immunotherapy: molecular Understanding of PD-1\/PD-L1 pathway & translational Blockade of immune checkpoints. Int J Mol Sci. 2016;17(7):1151. https:\/\/doi.org\/10.3390\/ijms17071151.","journal-title":"Int J Mol Sci"},{"issue":"suppl4","key":"15069_CR3","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"JB Haanen","year":"2017","unstructured":"Haanen JB, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl4):iv119\u201342. https:\/\/doi.org\/10.1093\/annonc\/mdx225.","journal-title":"Ann Oncol"},{"issue":"14","key":"15069_CR4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1709684.","journal-title":"N Engl J Med"},{"issue":"2","key":"15069_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3238\/arztebl.m2023.0242","volume":"121","author":"N Eisemann","year":"2024","unstructured":"Eisemann N, Schumann L, Baltus H, Labohm L, Kraywinkel K, Katalinic A. Longer survival from melanoma in Germany. Dtsch Arztebl Int. 2024;121(2):45\u201351. https:\/\/doi.org\/10.3238\/arztebl.m2023.0242.","journal-title":"Dtsch Arztebl Int"},{"issue":"14","key":"15069_CR6","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1056\/NEJMp1901103","volume":"380","author":"T Langbaum","year":"2019","unstructured":"Langbaum T, Smith TJ. Time to study metastatic-cancer survivorship. N Engl J Med. 2019;380(14):1300\u20132. https:\/\/doi.org\/10.1056\/NEJMp1901103.","journal-title":"N Engl J Med"},{"key":"15069_CR7","doi-asserted-by":"publisher","unstructured":"Bloom JR. Surviving and thriving? Psychooncology. 2002;11(2):89\u201392. https:\/\/doi.org\/10.1002\/pon.606","DOI":"10.1002\/pon.606"},{"issue":"1","key":"15069_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30573-3","volume":"18","author":"DK Mayer","year":"2017","unstructured":"Mayer DK, Nasso SF, Earp JA. Defining cancer survivors, their needs, and perspectives on survivorship health care in the USA. Lancet Oncol. 2017;1e11\u20138. https:\/\/doi.org\/10.1016\/S1470-2045(16)30573-3.","journal-title":"Lancet Oncol"},{"issue":"2","key":"15069_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.31887\/DCNS.2014.16.2\/mbullinger","volume":"16","author":"M Bullinger","year":"2014","unstructured":"Bullinger M, Quitmann J. Quality of life as patient-reported outcomes: principles of assessment. Dialogues Clin Neurosci. 2014;16(2):137\u201345. https:\/\/doi.org\/10.31887\/DCNS.2014.16.2\/mbullinger.","journal-title":"Dialogues Clin Neurosci"},{"key":"15069_CR10","volume-title":"Zur messbarkeit von Lebensqualit\u00e4t","author":"M Bullinger","year":"2016","unstructured":"Bullinger M. In: Kovacs L, Kipke R, Lutz R, editors. Zur messbarkeit von Lebensqualit\u00e4t. Wiesbaden: Springer; 2016."},{"issue":"9","key":"15069_CR11","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s11136-008-9396-4","volume":"17","author":"JM Valderas","year":"2008","unstructured":"Valderas JM, Alonso J. Patient reported outcome measures: a model-based classification system for research and clinical practice. Qual Life Res. 2008;17(9):1125\u201335. https:\/\/doi.org\/10.1007\/s11136-008-9396-4.","journal-title":"Qual Life Res"},{"key":"15069_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/POR.S350165","volume":"13","author":"F Wiedemann","year":"2022","unstructured":"Wiedemann F, Porzsolt F. Measuring health-related quality of life in randomised controlled trials: expected and reported results do not match. Pragmat Obs Res. 2022;13:9\u201316. https:\/\/doi.org\/10.2147\/POR.S350165.","journal-title":"Pragmat Obs Res"},{"key":"15069_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejca.2017.08.032","volume":"86","author":"TM Petrella","year":"2017","unstructured":"Petrella TM, Robert C, Richtig E, Miller WH Jr, Masucci GV, Walpole E, et al. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. Eur J Cancer. 2017;86:115\u201324. https:\/\/doi.org\/10.1016\/j.ejca.2017.08.032.","journal-title":"Eur J Cancer"},{"key":"15069_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ejca.2017.05.031","volume":"82","author":"D Schadendorf","year":"2017","unstructured":"Schadendorf D, Larkin J, Wolchok J, Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Health-related quality of life results from the phase III checkmate 067 study. Eur J Cancer. 2017;82:80\u201391. https:\/\/doi.org\/10.1016\/j.ejca.2017.05.031.","journal-title":"Eur J Cancer"},{"issue":"7","key":"15069_CR15","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ejca.2015.03.004","volume":"51","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, Amonkar MM, Stroyakovskiy D, et al. Health-related quality of life impact in a randomised phase III study of the combination of Dabrafenib and Trametinib versus Dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. Eur J Cancer. 2015;51(7):833\u201340. https:\/\/doi.org\/10.1016\/j.ejca.2015.03.004.","journal-title":"Eur J Cancer"},{"issue":"3","key":"15069_CR16","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1002\/cam4.5183","volume":"12","author":"C Chen","year":"2023","unstructured":"Chen C, Wang Z, Qin YR. Health-related quality of life in stage III-IV melanoma treated with targeted therapy or immunotherapy: a systematic review on the adequacy of reporting and clinical issues in phase III randomized controlled trials. Cancer Med. 2023;12(3):2262\u201380. https:\/\/doi.org\/10.1002\/cam4.5183.","journal-title":"Cancer Med"},{"issue":"5","key":"15069_CR17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"15069_CR18","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s11764-021-01160-1","volume":"17","author":"M van Leeuwen","year":"2023","unstructured":"van Leeuwen M, Kieffer JM, Young TE, Annunziata MA, Arndt V, Arraras JI, et al. Phase III study of the European organisation for research and treatment of cancer quality of life cancer survivorship core questionnaire. J Cancer Surviv. 2023;17(4):1111\u201330. https:\/\/doi.org\/10.1007\/s11764-021-01160-1.","journal-title":"J Cancer Surviv"},{"issue":"9","key":"15069_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju244","volume":"106","author":"E Basch","year":"2014","unstructured":"Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, et al. Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9):dju244. https:\/\/doi.org\/10.1093\/jnci\/dju244.","journal-title":"J Natl Cancer Inst"},{"key":"15069_CR20","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2022.10.026","volume":"178","author":"K Cocks","year":"2023","unstructured":"Cocks K, Wells JR, Johnson C, Schmidt H, Koller M, Oerlemans S, et al. Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer. Eur J Cancer. 2023;178:128\u201338. https:\/\/doi.org\/10.1016\/j.ejca.2022.10.026.","journal-title":"Eur J Cancer"},{"key":"15069_CR21","volume-title":"The EORTC scoring manual","author":"PM Fayers","year":"2001","unstructured":"Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, et al. The EORTC scoring manual. 3rd ed. editors. Brussels: European Organisation for Research and Treatment of Cancer; 2001.","edition":"3"},{"issue":"24","key":"15069_CR22","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1093\/jnci\/djr485","volume":"103","author":"C Quinten","year":"2011","unstructured":"Quinten C, Maringwa J, Gotay CC, et al. Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst. 2011;103(24):1851\u20138. https:\/\/doi.org\/10.1093\/jnci\/djr485.","journal-title":"J Natl Cancer Inst"},{"key":"15069_CR23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ejca.2020.06.002","volume":"137","author":"S Nolte","year":"2020","unstructured":"Nolte S, Waldmann A, Liegl G, Petersen MA, Groenvold M, Rose M. Updated EORTC QLQ-C30 general population norm data for Germany. Eur J Cancer. 2020;137:161\u201370. https:\/\/doi.org\/10.1016\/j.ejca.2020.06.002.","journal-title":"Eur J Cancer"},{"issue":"6","key":"15069_CR24","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/bjc.2017.488","volume":"118","author":"B Dr\u00e9no","year":"2018","unstructured":"Dr\u00e9no B, Ascierto P, Atkinson V, et al. Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation\u2013positive melanoma. Br J Cancer. 2018;118(6):777\u201384. https:\/\/doi.org\/10.1038\/bjc.2017.488.","journal-title":"Br J Cancer"},{"key":"15069_CR25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2021.04.028","volume":"152","author":"H Gogas","year":"2021","unstructured":"Gogas H, Dummer R, Ascierto PA, et al. Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: results from a multicentre, open-label, randomised, phase III study (COLUMBUS). Eur J Cancer. 2021;152:116\u201328. https:\/\/doi.org\/10.1016\/j.ejca.2021.04.028.","journal-title":"Eur J Cancer"},{"key":"15069_CR26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejca.2016.07.018","volume":"67","author":"D Schadendorf","year":"2016","unstructured":"Schadendorf D, Dummer R, Hauschild A, et al. Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. Eur J Cancer. 2016;67:46\u201354. https:\/\/doi.org\/10.1016\/j.ejca.2016.07.018.","journal-title":"Eur J Cancer"},{"issue":"6","key":"15069_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-4025-9","volume":"26","author":"WY Cheung","year":"2018","unstructured":"Cheung WY, Bayliss MS, White MK, Stroupe A, Lovley A, King-Kallimanis BL, et al. Humanistic burden of disease for patients with advanced melanoma in Canada. Support Care Cancer. 2018;61985\u201391. https:\/\/doi.org\/10.1007\/s00520-017-4025-9.","journal-title":"Support Care Cancer"},{"key":"15069_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113601","volume":"200","author":"M Egeler","year":"2024","unstructured":"Egeler M, Lai-Kwon J, Tissier R, et al. Real-world health-related quality of life outcomes for patients with resected stage III\/IV melanoma treated with adjuvant anti-PD1 therapy. Eur J Cancer. 2024;200:113601. https:\/\/doi.org\/10.1016\/j.ejca.2024.113601.","journal-title":"Eur J Cancer"},{"key":"15069_CR29","doi-asserted-by":"publisher","unstructured":"Warner BM, Baer AN, Lipson EJ, Allen C, Hinrichs C, Rajan A. Et aI. Sicca syndrome associated with immune checkpoint inhibitor therapy. Oncologist. 2019;91259\u201369. https:\/\/doi.org\/10.1634\/theoncologist.2018-0823.","DOI":"10.1634\/theoncologist.2018-0823"},{"issue":"3","key":"15069_CR30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00520-010-0865-2","volume":"19","author":"WY Cheung","year":"2011","unstructured":"Cheung WY, Le LW, Gagliese L, Zimmermann C. Age and gender differences in symptom intensity and symptom clusters among patients with metastatic cancer. Support Care Cancer. 2011;19(3):417\u201323. https:\/\/doi.org\/10.1007\/s00520-010-0865-2.","journal-title":"Support Care Cancer"},{"issue":"3","key":"15069_CR31","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s005200050281","volume":"8","author":"D Walsh","year":"2000","unstructured":"Walsh D, Donnelly S, Rybicki L. The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer. 2000;8(3):175\u20139. https:\/\/doi.org\/10.1007\/s005200050281.","journal-title":"Support Care Cancer"},{"issue":"1","key":"15069_CR32","doi-asserted-by":"publisher","first-page":"e000260","DOI":"10.1136\/jitc-2019-000260","volume":"8","author":"M Mamoor","year":"2020","unstructured":"Mamoor M, Postow MA, Lavery JA, Baxi SS, Khan N, Mao JJ, et al. Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors. J Immunother Cancer. 2020;8(1):e000260. https:\/\/doi.org\/10.1136\/jitc-2019-000260.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"15069_CR33","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254\u201367. https:\/\/doi.org\/10.1038\/s41571-022-00600-w.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"15069_CR34","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1186\/s12889-018-5401-1","volume":"18","author":"S Fischbeck","year":"2018","unstructured":"Fischbeck S, Weyer-Elberich V, Zeissig SR, Imruck BH, Blettner M, Binder H, et al. Determinants of illness-specific social support and its relation to distress in long-term melanoma survivors. BMC Public Health. 2018;18(1):511. https:\/\/doi.org\/10.1186\/s12889-018-5401-1.","journal-title":"BMC Public Health"},{"issue":"19","key":"15069_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194823","volume":"15","author":"A Rogiers","year":"2023","unstructured":"Rogiers A, Willemot L, McDonald L, et al. Real-world effectiveness, safety, and health-related quality of life in patients receiving adjuvant nivolumab for melanoma in Belgium and Luxembourg: results of preserv mel. Cancers (Basel). 2023;15(19):4823. https:\/\/doi.org\/10.3390\/cancers15194823.","journal-title":"Cancers (Basel)"},{"key":"15069_CR36","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/2192480","volume":"2020","author":"A Rogiers","year":"2020","unstructured":"Rogiers A, Leys C, Lauwyck J, Schembri A, Awada G, Schwarze JK, et al. Neurocognitive function, psychosocial outcome, and health-related quality of life of the first-generation metastatic melanoma survivors treated with ipilimumab. J Immunol Res. 2020;2020:2192480. https:\/\/doi.org\/10.1155\/2020\/2192480.","journal-title":"J Immunol Res"},{"issue":"5","key":"15069_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100276","volume":"6","author":"M Garutti","year":"2021","unstructured":"Garutti M, Lambertini M, Puglisi F. Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review. ESMO Open. 2021;6(5):100276. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100276.","journal-title":"ESMO Open"},{"key":"15069_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2021.04.031","volume":"152","author":"M Salzmann","year":"2021","unstructured":"Salzmann M, Tosev G, Heck M, Schadendorf D, Maatouk I, Enk AH, et al. Male fertility during and after immune checkpoint inhibitor therapy: a cross-sectional pilot study. Eur J Cancer. 2021;152:41\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2021.04.031.","journal-title":"Eur J Cancer"},{"key":"15069_CR39","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3238\/arztebl.2020.0653","volume":"117","author":"P Briken","year":"2020","unstructured":"Briken P, Matthiesen S, Pietras L, Wiessner C, Klein V, Reed GM, et al. Estimating the prevalence of sexual dysfunction using the new ICD-11 guidelines\u2014results of the first representative, population-based German health and sexuality survey (GeSiD). Dtsch Arztebl Int. 2020;117:653\u20138. https:\/\/doi.org\/10.3238\/arztebl.2020.0653.","journal-title":"Dtsch Arztebl Int"},{"issue":"2","key":"15069_CR40","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.1016\/S1470-2045(22)00654-4","volume":"24","author":"C Piccinin","year":"2023","unstructured":"Piccinin C, Basch E, Bhatnagar V, et al. Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group. Lancet Oncol. 2023;24(2):e86\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(22)00654-4.","journal-title":"Lancet Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15069-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15069-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15069-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:16:58Z","timestamp":1760617018000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15069-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15069"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15069-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research involving human subjects was reviewed and approved by the ethics committee of TU Dresden, reference number: SR\u2009+\u2009BO-EK-184042023. Informed consent was obtained from all study participants in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JS reports institutional grants for investigator-initiated research from the German Federal Joint Committee, German Ministry of Health, German Ministry of Research, European Union, German Federal State of Saxony, Novartis, Sanofi, ALK, and Pfizer. He participated in advisory board meetings as a paid consultant for Sanofi, Lilly, and ALK. Prof. Schmitt serves the German Ministry of Health as a member of the German National Council for Health and Care.Independently of this study, OS was a paid consultant for Novartis. He is also a member of the certification committee \u201cSkin Cancer Centers\u201d of the German Cancer Society and a member of the panel of experts for the project \u201cResearch into criteria to evaluate certificates and quality seals in accordance with Sec. 137a para. 3 sentence 2 No. 7 SGB V\u201d for the Institute for Quality Assurance and Transparency in Healthcare (IQTIG).The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1599"}}